Using metaphase fluorescence in situ hybridization (FISH) to narrow translocation breakpoints and polymerase chain reaction (PCR) to identify genes, we detected the TPM3 gene at 1q21 as a new PDGFRB partner in chronic eosinophilic leukemia (CEL). CEL is defined by a persistent eosinophil count X1.5 Â 10 9 /l with no known underlying causes, organ involvement, evidence of eosinophil clonality or increased blasts. In 30-40% of patients with male predominance and high incidence of hepatomegaly and splenomegaly, CEL is associated with del(4)(q12)/FIP1L1-PDGFRA genomic change. Rare cases show 5q31-q33 rearrangements, in a few of which PDGFRB is involved. 1 Interestingly, a t(1;5)(q21;q33) disrupting PDGFRB has been reported in one case classified as atypical chronic myeloid leukemia (aCML)/CEL. 2 In 1991, a 21-year-old man with CEL showed a 46,XY, t(1;5)(q21;q33) karyotype in 28/29 metaphases. 3 Under a-interferon treatment, which was administered for 10 years, the patient obtained a major cytogenetic response. In April 2002, imatinib therapy provided hematological, cytogenetic and FISH remission, which was maintained until the last checkup in January 2005.
Metaphase FISH was performed using a bone marrow sample taken at diagnosis. Cosmid 9-4 for the 3 0 PDGFRB (green) and cosmid 4-1 for the 5 0 PDGFRB (red) gave a red/green fusion signal on normal 5, a green signal on der(5) and a red signal on der(1) indicating PDGFRB was rearranged. The long arm of chromosome 1 was examined with a panel of 17 DNA clones mapping at bands 1q21-q23 (from centromere to telomere:
The breakpoint fell within clone RP11-205M9, which gave three hybridization signals on normal chromosome 1, on der(1) and on der(5). All the other clones gave two hybridization signals: those more centromeric than RP11-205M9 on normal 1 and on der(1), and those more telomeric on normal 1 and on der(5).
The RP11-205M9 clone mapping at the 1q21.2 band corresponds to a region that contains the following genes: C1orf43, the ubiquitin associated protein 2-like (UBAP2L) and tropomyosin 3 (TPM3).
A TPM3/PDGFRB fusion transcript was amplified by seminested reverse transcriptase (RT)-PCR. Patient RNA was extracted with Trizol (Invitrogen, Carlsbad, CA, USA) from a bone marrow sample taken at diagnosis and retro-transcribed using the Thermoscript RT-PCR System (Invitrogen) (Figure 1a) . The first round of amplification was performed with primers TPM3_425F (AGGTGGCTCGTAAGTTGGTG) and PDGFRB_2369R (TAGATGGGTCCTCCTTTGGTG) and the second with primers TPM3_425F and PDGFRBR1 (TAAG CATCTTGACGGCCACT). The product was cloned in pGEM-T Easy Vector System (Promega, Madison, WI, USA). Sequencing confirmed amplification of a chimeric transcript fusing exon 7 of TPM3 isoform 2 (GenBank accession no. NM_153649) with exon 11 of PDGFRB (Figure 1b) . The reciprocal PDGFRB/ TPM3 fusion transcript was sought by RT-PCR using primers PDGFRB_1686F (CCGAACATCATCTGGTCTGC) and TPM3v2_1158R (GGATTCGATTGCTGCTTCAG), followed by nested PCR with primers PDGFRB-1810F (AGGAGCAG GAGTTTGAGGTG) and TPM3_919R (GGTGGTGAAAGGA GAAAGCA). We detected and sequenced a PDGFRB/TPM3 fusion transcript joining exon 10 of PDGFRB to exon 8 of TPM3 (data not shown). So one case of imatinib mesylate-sensitive CEL with t(1;5)(q21;q33) is, for the first time, observed to produce TPM3/PDGFRB with its reciprocal PDGFRB/TPM3 fusion.
TPM3 is an actin-binding protein whose muscle isoform mediates myosin-actin response to calcium ions in skeletal muscles and whose non-muscle isoform is found in cytoskeletal microfilaments. A heterozygous TPM3 germline mutation is associated with the autosomal dominant form of nemaline myopathy. 4 When fused to tyrosine kinases, TPM3 participates with its 221 NH 2 -terminal amino acids (encoded by exons 1-7), which contain the coiled-coil dimerization domain. 5 In anaplastic cell lymphomas and in inflammatory myofibroblastic tumors with t(1;2)(q25;p23), TPM3 gene rearranges with ALK (anaplastic cell lymphoma kinase). In colon carcinoma and in papillary thyroid carcinomas, TPM3 rearranges with the nearby neurotrophic tyrosine kinase, receptor, type 1 (NTRK1/1q23) gene. 5 In 20% of human papillary thyroid carcinomas, the H4/ D10S170 gene, at 10q21, is partner of the receptor tyrosine kinase RET in the inv(10)(q11.2q21). 6 Interestingly, the H4/ D10S170 gene is another partner of PDGFRB, in aCML with t(5;10)(q33;q21). 7 A common structural feature of TPM3 and H4/D10S170 proteins is the coiled-coil domain, which contributes with its dimerization/activation moiety to building tyrosine kinase fusion proteins.
Given these findings, a double color double fusion FISH assay with clone CTD-2601I11 encompassing the PDGFRB breakpoint, and clone RP11-205M9 for TPM3 (Figure 2 ) is a valid diagnostic test for discriminating between t(1;5)(q21;q33)/ TPM3/PDGFRB, as described in the present letter, and t(1;5) involving other genes at 1q21-q23 such as PDE4DIP-PDGFRB, which has been reported in a pediatric case of chronic myeloproliferative disorder. 8 
Figure 2
FISH identifies the breakpoints in chromosomes 1 and 5. Double color double fusion experiment with CTD-2601I11 (green) and RP11-205M9 (red) gives a red signal on normal 1, a green signal on normal 5 and a red/green fusion signal on both der(1) and der(5) (arrows). Determination of specific chromosomal abnormalities plays an important role in the diagnosis, prognosis and management of hematological malignancies. Double minute chromosomes (dmins) are small chromatin bodies consisting of genes that are amplified in an extrachromosomal location. They are the genetic vehicles for amplifying oncogenes and drug-resistance genes. Such gene amplification events are frequently associated with tumor progression. Identification of dmins in hematologic malignancies has been reported primarily in acute myeloid leukemia. Recognized genes in the dmins include MYC oncogene and MLL transcription factor. 1, 2 However, the occurrence of dmins is rare in lymphoid malignancies. Specific
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